FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) is working on a dementia diagnosis support AI system in collaboration with Keio University School of Medicine (Location: Shinjuku-ku, Tokyo). We have received a notice of patent decision from the Japan Patent Office.

Application number: Special application 2018-170847 * Registration number not given

Patent filing date: January 2018, 9

(By joint application with Keio University)

The dementia diagnosis support AI system is the first system in Japan that enables the diagnosis of dementia, which was previously difficult unless a specialist, can be performed in a short time from natural daily conversation.By putting this system into practical use, not only will it be possible to support dementia diagnosis in areas where there are no specialists or in situations where it is not possible to meet directly with doctors, but it will also be possible in the future due to the characteristics of not being restricted by time and place. In Japan, which is facing an aging society, it can be applied to a wider range of applications such as telemedicine and improving the efficiency of medical care.

• About dementia diagnosis support AI system URL: https://lifescience.fronteo.com/operations/

The dementia diagnosis support AI system is FRONTEO's original natural language analysis AI "Concept Encoder (registered trademark: concept encoder).^®) ”Is a system that can screen for cognitive dysfunction from daily conversation between the patient and the doctor for about 5 to 10 minutes.We believe that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which is facing a super-aging society. I will. FRONTEO entered into a business alliance agreement with Kyowa Yakuhin Kogyo Co., Ltd., which aims to become a CNS (central nervous system) total solution company, in June 2020, aiming for early commercialization and early market penetration in the medical field.

• concept encoderabout URL: https://lifescience.fronteo.com/concept-encoder/

"Concept Encoder (registered trademark: concept encoder)^®, Reading: Concept Encoder) ”is FRONTEO's unique life science field-specific natural language analysis AI (artificial intelligence).It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

• FRONTEOabout URL: https://www.fronteo.com/

FRONTEO Inc. has developed its own natural language analysis AI (artificial intelligence) engine "KIBIT".^®(Kibit) "and" concept encoder^®(Concept encoder) ”is a company that supports information analysis.Established in August 2003 as a company that supports e-discovery (electronic discovery), which preserves evidence, investigates and analyzes electronic data necessary for international proceedings, and digital forensic investigations, and technologies such as an in-house developed data analysis platform To date, we have supported about 8 international proceedings.In addition, we are applying the unique AI-related technology cultivated in the legal business to areas such as life science and business intelligence, and have achieved results in drug discovery research support, diagnostic support, and work style reform. Listed on TSE Mothers on June 1, 2007.The capital is 6 thousand yen (as of March 26, 2,568,651).

• Notices

This research and development is a medical device and system research and development project (medical support technology research and development project utilizing ICT) that realizes future medical care of the Japan Agency for Medical Research and Development (AMED) "Facial expression, voice, daily life activities" This was done with the support of "Development of a device that delivers an objective evaluation of mental symptoms in real time from the quantification of."